Issue Date: December 3, 2012
Sanofi And Selecta Target Allergies
Sanofi and Selecta Biosciences are joining to develop antigen-specific immunotherapies for allergies using Selecta’s synthetic vaccine particle technology. Under the agreement, Sanofi obtains an exclusive license to develop an immunotherapy against a life-threatening food allergen and an option to develop two more allergy therapies. Selecta can receive milestone payments totaling up to $300 million for each of the three drug candidates. Selecta was founded in 2008 by MIT professor Robert Langer and two Harvard Medical School professors.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society